These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24404139)

  • 1. Celecoxib ameliorates non-alcoholic steatohepatitis in type 2 diabetic rats via suppression of the non-canonical Wnt signaling pathway expression.
    Tian F; Zhang YJ; Li Y; Xie Y
    PLoS One; 2014; 9(1):e83819. PubMed ID: 24404139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Non-canonical Wnt signaling contributes to development of non-alcoholic steatohepatitis in a rat model of type 2 diabetes mellitus].
    Tian F; Zhang YJ; Wang L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Jul; 21(7):537-42. PubMed ID: 24074715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celecoxib attenuates liver steatosis and inflammation in non-alcoholic steatohepatitis induced by high-fat diet in rats.
    Chen J; Liu D; Bai Q; Song J; Guan J; Gao J; Liu B; Ma X; Du Y
    Mol Med Rep; 2011; 4(5):811-6. PubMed ID: 21643627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of celecoxib on expression of PPARγ and NF-κB in type 2 diabetes rats with non-alcoholic steatohepatitis].
    Tian F; Zhang YJ; Wang YH
    Zhonghua Gan Zang Bing Za Zhi; 2016 Aug; 24(8):590-595. PubMed ID: 27788706
    [No Abstract]   [Full Text] [Related]  

  • 5. [Mechanism study of the protective effects of selective cyclooxygenase-2 enzyme inhibitors on the liver of rats with type 2 diabetes mellitus combined with nonalcoholic steatohepatitis via Rho/ROCK pathway].
    Yuan L; Tian F
    Zhonghua Gan Zang Bing Za Zhi; 2022 Jan; 30(1):74-80. PubMed ID: 35152673
    [No Abstract]   [Full Text] [Related]  

  • 6. Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver.
    Lu CH; Hung YJ; Hsieh PS
    Eur J Pharmacol; 2016 Oct; 789():60-67. PubMed ID: 27397427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase-2 promotes hepatocellular apoptosis by interacting with TNF-α and IL-6 in the pathogenesis of nonalcoholic steatohepatitis in rats.
    Cheng Q; Li N; Chen M; Zheng J; Qian Z; Wang X; Huang C; Xu S; Shi G
    Dig Dis Sci; 2013 Oct; 58(10):2895-902. PubMed ID: 23975340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
    Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
    J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib decreases fatty acid synthase expression via down-regulation of c-Jun N-terminal kinase-1.
    Lu S; Archer MC
    Exp Biol Med (Maywood); 2007 May; 232(5):643-53. PubMed ID: 17463161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of the HIF-1α and Wnt/β-catenin pathways in the protective effects of losartan on fatty liver graft with ischaemia/reperfusion injury.
    Yang YY; Lee PC; Huang YT; Lee WP; Kuo YJ; Lee KC; Hsieh YC; Lee TY; Lin HC
    Clin Sci (Lond); 2014 Jan; 126(2):163-74. PubMed ID: 23875703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of traditional chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis.
    Gao Y; Song LX; Jiang MN; Ge GY; Jia YJ
    Inflammation; 2008 Apr; 31(2):121-32. PubMed ID: 18302012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone ameliorates nonalcoholic steatohepatitis by down-regulating hepatic nuclear factor-kappa B and cyclooxygenases-2 expression in rats.
    Zhao JS; Zhu FS; Liu S; Yang CQ; Chen XM
    Chin Med J (Engl); 2012 Jul; 125(13):2316-21. PubMed ID: 22882855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver.
    Hsieh PS; Jin JS; Chiang CF; Chan PC; Chen CH; Shih KC
    Obesity (Silver Spring); 2009 Jun; 17(6):1150-7. PubMed ID: 19247274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrvinium pamoate attenuates non-alcoholic steatohepatitis: Insight on hedgehog/Gli and Wnt/β-catenin signaling crosstalk.
    El-Derany MO; El-Demerdash E
    Biochem Pharmacol; 2020 Jul; 177():113942. PubMed ID: 32240652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide in combination with human umbilical cord mesenchymal stem cell could improve liver lesions by modulating TLR4/NF-kB inflammatory pathway and oxidative stress in T2DM/NAFLD rats.
    Xu X; Wang W; Lin L; Chen P
    Tissue Cell; 2020 Oct; 66():101382. PubMed ID: 32933722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation.
    Kabil SL; Mahmoud NM
    Eur J Pharmacol; 2018 Jun; 828():135-145. PubMed ID: 29608898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppressing cyclooxygenase-2 prevents nonalcoholic and inhibits apoptosis of hepatocytes that are involved in the Akt/p53 signal pathway.
    Wu J; Chen C; Hu X; Cai X; Guan Y; Hu H; Wang Q; Chen X; Cai B; Jing X
    Biochem Biophys Res Commun; 2016 Jan; 469(4):1034-40. PubMed ID: 26723251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 20. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells.
    Kim M; Yang SG; Kim JM; Lee JW; Kim YS; Lee JI
    Int J Mol Med; 2012 Sep; 30(3):473-9. PubMed ID: 22710359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.